Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

To join this study, participants must be at least 18 years old and generally in good health, with an expected lifespan of at least six months. Your body should be able to make enough blood cells (like platelets and white blood cells), and your kidneys and liver should be working fairly well.

Specifically for patients with multiple myeloma, you would need to have tried at least five different treatments before, including specific types of drugs such as proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. Your multiple myeloma would also need to have grown or not responded to these previous treatments. You might also be eligible if you have certain other B-cell cancers and have had prior treatments.

The study team will carefully review your medical history and test results to see if this study is right for you. They will explain all the requirements in detail.

The information provided does not give specific details about the number of hospital visits, duration of treatment, or follow-up schedule. However, based on the type of intervention (single, multiple, or fractionated doses of a targeted radiotherapeutic), it's likely that participation would involve:

* **Initial screening:** A series of tests and checks to confirm eligibility. * **Treatment administration:** Receiving the Iopofosine I-131 medicine intravenously (into a vein). The study mentions single, multiple, or fractionated doses, which means you might receive the treatment once, several times, or in smaller amounts over a period. * **Monitoring:** Regular check-ups, blood tests, and scans to monitor your health, how you're responding to the treatment, and any side effects. * **Follow-up:** Continued observation after the treatment period to track your long-term health and the lasting effects of the medication. The total duration of participation and specific schedule would be fully explained by the study team.